Nanoparticles as synthetic vaccines

Current Opinion in Biotechnology

Volumn 34, Issue , 2015, Pages 217-224

  Smith, Josiah D ^a   Morton, Logan D ^a   Ulery, Bret D ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLES;

BIO-MOLECULAR; CONTROLLED RELEASE; IMMUNE CELLS; IMMUNE RESPONSE; IMMUNOGENICITY; SIDE EFFECT; SYNTHETIC VACCINES;

VACCINES;

ALUMINUM NANOPARTICLE; BCG VACCINE; CALCIUM PHOSPHATE NANOPARTICLE; CHITOSAN; GOLD NANOPARTICLE; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYALURONIC ACID; IMMUNOLOGICAL ADJUVANT; ISCOM; LIPOSOME; NANOPARTICLE; POLYANHYDRIDE; POLYGLACTIN; RECOMBINANT VACCINE; SILICATE NANOPARTICLE; TETANUS TOXOID; UNCLASSIFIED DRUG; WART VIRUS VACCINE; MICELLE;

ANTIGEN FUNCTION; BIOCOMPATIBILITY; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; MICELLE; NANOBIOTECHNOLOGY; NANOFABRICATION; NONHUMAN; ORGANIC CHEMISTRY; PRIORITY JOURNAL; REVIEW; TARGET CELL; TUBERCULOSIS; VIRUS LIKE AGENT; ANIMAL; ANTIBODY PRODUCTION; CHEMISTRY; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; HUMANS; LIPOSOMES; MICELLES; NANOPARTICLES; VACCINES, SYNTHETIC;

EID: 84926473430     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2015.03.014     Document Type: Review

References (52)

1. Bansal V., Kumar M., Dalela M., Brahmne H.G., Singh H. Evaluation of synergistic effect of biodegradable polymeric nanoparticles and aluminum based adjuvant for improving vaccine efficacy. Int J Pharm 2014, 471:377-384.
2. Maquieira A., Brun E.M., Garces-Garcia M., Puchades R. Aluminum oxide nanoparticles as carriers and adjuvants for eliciting antibodies from non-immunogenic haptens. Anal Chem 2012, 84:9340-9348.
3. Sun B., Ji Z., Liao Y.P., Wang M., Wang X., Dong J., Chang C.H., Li R., Zhang H., Nel A.E., et al. Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano 2013, 7:10834-10849.
4. Chen Y.S., Hung Y.C., Lin W.H., Huang G.S. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 2010, 21:195101.
5. Barhate G., Gautam M., Gairola S., Jadhav S., Pokharkar V. Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment. J Pharm Sci 2014, 11:3448-3456.
6. Gregory A.E., Judy B.M., Qazi O., Blumentritt C.A., Brown K.A., Shaw A.M., Torres A.G., Titball R.W. A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine 2015, 11:447-456.
7. Guo H.C., Feng X.M., Sun S.Q., Wei Y.Q., Sun D.H., Liu X.T., Liu Z.X., Luo J.X., Yin H. Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein. Virol J 2012, 9:108.
8. Wibowo N., Chuan Y.P., Seth A., Cordoba Y., Lua L.H., Middelberg A.P. Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation. Vaccine 2014, 32:3664-3669.
9. Temchura V.V., Kozlova D., Sokolova V., Uberla K., Epple M. Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen. Biomaterials 2014, 35:6098-6105.
10. Zhou W., Moguche A.O., Chiu D., Murali-Krishna K., Baneyx F. Just-in-time vaccines: biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice. Nanomedicine 2014, 10:571-578.
11. Knuschke T., Bayer W., Rotan O., Sokolova V., Wadwa M., Kirschning C.J., Hansen W., Dittmer U., Epple M., Buer J., et al. Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection. Nanomedicine 2014, 10:1787-1798.
12. Zhao K., Zhang Y., Zhang X., Li W., Shi C., Guo C., Dai C., Chen Q., Jin Z., Zhao Y., et al. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles. Int J Nanomed 2014, 9:389-402.
13. Li L., Lin S.-L., Deng L., Liu Z.-G. Potential use of chitosan nanoparticles for oral delivery of DNA vaccine in black seabream Acanthopagrus schlegelii Bleeker to protect from Vibrio parahaemolyticus. J Fish Dis 2013, 36:987-995.
14. Oyarzun-Ampuero F.A., Goycoolea F.M., Torres D., Alonso M.J. A new drug nanocarrier consisting of polyarginine and hyaluronic acid. Eur J Pharm Biopharm 2011, 79:54-57.
15. Gu G., Adabala P.J., Szczepina M.G., Borrelli S., Pinto B.M. Synthesis and immunological characterization of modified hyaluronic acid hexasaccharide conjugates. J Org Chem 2013, 78:8004-8019.
16. Verheul R.J., Slutter B., Bal S.M., Bouwstra J.A., Jiskoot W., Hennink W.E. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination. J Control Release 2011, 156:46-52.
17. Toita R., Kanai Y., Watabe H., Nakao K., Yamamoto S., Hatazawa J., Akashi M. Biodistribution of (125)I-labeled polymeric vaccine carriers after subcutaneous injection. Bioorg Med Chem 2013, 21:5310-5315.
18. Schliehe C., Schliehe C., Thiry M., Tromsdorf U.I., Hentschel J., Weller H., Groettrup M. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J Control Release 2011, 151:278-285.
19. Binjawadagi B., Dwivedi V., Manickam C., Ouyang K., Wu Y., Lee L.J., Torrelles J.B., Renukaradhya G.J. Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs. Int J Nanomed 2014, 9:679-694.
20. Tongtong M., Wang L., Yang T., Ma G., Wang S. Homogeneous PLGA-lipid nanoparticle as a promising oral vaccine delivery system for ovalbumin. Asian J Pharm Sci 2014, 9:129-136.
21. Ulery B.D., Petersen L.K., Phanse Y., Kong C.S., Broderick S.R., Kumar D., Ramer-Tait A.E., Carrillo-Conde B., Rajan K., Wannemuehler M.J., et al. Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. Sci Rep 2011, 1:198.
22. Haughney S.L., Petersen L.K., Schoofs A.D., Ramer-Tait A.E., King J.D., Briles D.E., Wannemuehler M.J., Narasimhan B. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles. Acta Biomater 2013, 9:8262-8271.
23. Phanse Y., Carrillo-Conde B.R., Ramer-Tait A.E., Broderick S., Kong C.S., Rajan K., Flick R., Mandell R.B., Narasimhan B., Wannemuehler M.J. A systems approach to designing next generation vaccines: combining alpha-galactose modified antigens with nanoparticle platforms. Sci Rep 2014, 4:3775.
24. Torres M.P., Wilson-Welder J.H., Lopac S.K., Phanse Y., Carrillo-Conde B., Ramer-Tait A.E., Bellaire B.H., Wannemuehler M.J., Narasimhan B. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater 2011, 7:2857-2864.
25. Zhao L., Wibowo S.A., Zhao N., Mitter C.X., Yu N., Middleburg C.A.P.J. Nanoparticle vaccines. Vaccine 2014, 32:327-337.
26. Gregory A.E., Williamson T.R.D. Vaccine delivery using nanoparticles. Cell Infect Microbiol 2013, 3:1-13.
27. Kraft J.C., Wang F.J., Ho Z.R.J.Y. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 2014, 103:29-52.
28. RAS Liposomes as vaccine delivery systems: a review of the recent advances. Therap Adv Vaccines 2014, 2:159-182.
29. Wang N., Zhang W.T., Chen M., Niu R., Deng R.Y. Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system. Eur J Pharm Biopharm 2014, 88:194-206.
30. Orr M.T., Baldwin F.C., Sivananthan S.L., Lucas S.J., Lin E., Phan S., Moon T., Vedvick J.J., Reed T.S., Coler S.G.R.N. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release 2013, 172:190-200.
31. Felnerova D., Gluck V.J., Moser R.C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004, 15:518-529.
32. Monto A.S., Aspinall A.F., McElhaney R., Montaño J.E., Nichol L.F., Puig-Barbarà K.L., Schmitt J., Stephenson J.I. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009, 27:5043-5053.
33. Srinivasan A., Ayyavoo R.A., Srivastava V.S. Nanotechnology-based approaches for the development of diagnostics, therapeutics, and vaccines. Monoclonal Antibodies Immunodiag Immunotherapy 2014, 33:186-191.
34. Rodríguez-Limas W.A., Tyo S.K.K.E.J. Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development. Curr Opin Biotechnol 2013, 24:1089-1093.
35. Noad R.R.P. Virus-like particles as immunogens. Trends Microbiol 2003, 11:438-444.
36. Grimm S.K.A.M. Vaccine design: emerging concepts and renewed optimism. Curr Opin Biotechnol 2013, 24:1078-1088.
37. Bissett S.L., Mattiuzzo G., Draper E., Godi A., Wilkinson D.E., Minor P., Page M., Beddows S. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins. Vaccine 2014, 33:6548-6555.
38. Zhang N., Bader W.P.R.A. Polysaccharide-based micelles for drug delivery. Pharmaceutics 2013, 5:329-352.
39. VPT Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001, 73:137-172.
40. Jiménez-Sánchez G., Chane-Haong P.V., Handké C., Terrat N., Gigmes C., Trimaille D., Verrier T.B. Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants. Pharm Res 2014, 32:311-320.
41. Liu H., Zheng M.K., Szeto Y., Li G.L., Huang A.V., Van Egeren B., Park D.S., Irvine C.D.J. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014, 507:519-521.
42. Black M., Olive T.A., Tirrell C.M. Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Exp Rev Vaccines 2010, 9:157-173.
43. Black M., Trent A., Kostenko Y., Lee J.S., Olive C., Tirrell M. Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. Adv Mater 2012, 24:3845-3849.
44. Trent A., Ulery B.D., Black M.J., Barrett J.C., Liang S., Kostenko Y., David N.A., Tirrell M.V. Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination. AAPS J 2014, 17:380-388.
45. Keller S., Patilea W.J., Kern G.I., Convertine H.B., Stayton A.J.P.S. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8+ T cell responses. J Control Release 2014, 191:24-33.
46. Accardo A., Tesauro V.M., Galdiero D., Finamore M., Martora E., Mansi F., Ringhieri R., Morelli P.G. Self-assembled or mixed peptide amphiphile micelles from Herpes simplex virus glycoproteins as potential immunomodulatory treatment. Int J Nanomed 2014, 9:2137-2148.
47. Sanders M.T., Deliyannis B.L., Pearse G.M.J. ISCOMTM-based vaccines: the second decade. Immunol Cell Biol 2005, 83:119-128.
48. Waite D.C., Ennis J.E., Edelman F.A., White R., Kammer B., Anderson R., Kensil C.C.R. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001, 19:3957-3967.
49. Hägglund S., Blodörn H.K., Makabi-Panzu K., Gaillard B., Ellencrona A.L., Chevret K., Hellman D., Bengtsson L., Riffault K.L., Taylor S., et al. Characterization of an experimental vaccine for bovine respiratory syncytial virus. Clin Vaccine Immunol 2014, 21:997-1004.
50. Pearse M.J.D.D. ISCOMATRIX® adjuvant for antigen delivery. Adv Drug Deliv Rev 2005, 57:465-474.
51. Morelli A.B., Koernig B.D., Silva S., Drane A., Maraskovksy D.E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012, 61:935-943.
52. Buglione-Corbett R., Marty-Roix P.K., Li R., West W., Wang K., Morelli S., Lien A.B., Lu E.S. Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine. Hum Vaccines Immunotherap 2014, 10:1078-1090.